PDF(Pubmed)
Abstract：
BACKGROUND: The safety and efficacy of vaccination against coronavirus disease 2019 (COVID-19) in patients with lymphangioleiomyomatosis (LAM) is still unclear. This study investigates COVID-19 vaccine hesitancy, vaccine safety and efficacy, and COVID-19 symptoms in LAM patients.
RESULTS: In total, 181 LAM patients and 143 healthy individuals responded to the questionnaire. The vaccination rate of LAM patients was 77.34%, and 15.7% of vaccinated LAM patients experienced adverse events. Vaccination decreased the risk of LAM patients developing anorexia [OR: 0.17, 95% CI: (0.07, 0.43)], myalgia [OR: 0.34, 95% CI: (0.13, 0.84)], and ageusia [OR: 0.34, 95% CI: (0.14, 0.84)]. In LAM patients, a use of mTOR inhibitors reduced the risk of developing symptoms during COVID-19, including fatigue [OR: 0.18, 95% CI: (0.03, 0.95)], anorexia [OR: 0.30, 95% CI: (0.09, 0.96)], and ageusia [OR: 0.20, 95% CI: (0.06, 0.67)].
CONCLUSIONS: Vaccination rates in the LAM population were lower than those in the general population, as 22.7% (41/181) of LAM patients had hesitations regarding the COVID-19 vaccine. However, the safety of COVID-19 vaccination in the LAM cohort was comparable to the healthy population, and COVID-19 vaccination decreased the incidence of COVID-19 symptoms in LAM patients. In addition, mTOR inhibitors seem not to determine a greater risk of complications in patients with LAM during COVID-19.
RESULTS: In total, 181 LAM patients and 143 healthy individuals responded to the questionnaire. The vaccination rate of LAM patients was 77.34%, and 15.7% of vaccinated LAM patients experienced adverse events. Vaccination decreased the risk of LAM patients developing anorexia [OR: 0.17, 95% CI: (0.07, 0.43)], myalgia [OR: 0.34, 95% CI: (0.13, 0.84)], and ageusia [OR: 0.34, 95% CI: (0.14, 0.84)]. In LAM patients, a use of mTOR inhibitors reduced the risk of developing symptoms during COVID-19, including fatigue [OR: 0.18, 95% CI: (0.03, 0.95)], anorexia [OR: 0.30, 95% CI: (0.09, 0.96)], and ageusia [OR: 0.20, 95% CI: (0.06, 0.67)].
CONCLUSIONS: Vaccination rates in the LAM population were lower than those in the general population, as 22.7% (41/181) of LAM patients had hesitations regarding the COVID-19 vaccine. However, the safety of COVID-19 vaccination in the LAM cohort was comparable to the healthy population, and COVID-19 vaccination decreased the incidence of COVID-19 symptoms in LAM patients. In addition, mTOR inhibitors seem not to determine a greater risk of complications in patients with LAM during COVID-19.
摘要：
背景：针对2019年冠状病毒病（COVID-19）的疫苗接种在淋巴管平滑肌瘤病（LAM）患者中的安全性和有效性尚不清楚。这项研究调查了COVID-19疫苗的犹豫，疫苗的安全性和有效性，LAM患者的COVID-19症状。
结果：总计，181名LAM患者和143名健康个体回答了问卷。LAM患者的接种率为77.34%,15.7%的接种疫苗的LAM患者出现不良事件。接种疫苗降低了LAM患者发生厌食症的风险[OR：0.17，95％CI：（0.07，0.43）]，肌痛[OR：0.34，95%CI：（0.13，0.84）]，和不适应[OR：0.34，95%CI：（0.14，0.84）]。在LAM患者中，使用mTOR抑制剂可降低COVID-19期间出现症状的风险，包括疲劳[OR：0.18，95％CI：（0.03，0.95）]，厌食症[OR：0.30，95%CI：（0.09，0.96）]，和不适应[OR：0.20，95%CI：（0.06，0.67）]。
结论：LAM人群的疫苗接种率低于一般人群，22.7%(41/181)的LAM患者对COVID-19疫苗有犹豫。然而,LAM队列中COVID-19疫苗接种的安全性与健康人群相当，和COVID-19疫苗接种降低了LAM患者COVID-19症状的发生率。此外,mTOR抑制剂似乎不能确定COVID-19期间LAM患者出现并发症的风险更大。
结果：总计，181名LAM患者和143名健康个体回答了问卷。LAM患者的接种率为77.34%,15.7%的接种疫苗的LAM患者出现不良事件。接种疫苗降低了LAM患者发生厌食症的风险[OR：0.17，95％CI：（0.07，0.43）]，肌痛[OR：0.34，95%CI：（0.13，0.84）]，和不适应[OR：0.34，95%CI：（0.14，0.84）]。在LAM患者中，使用mTOR抑制剂可降低COVID-19期间出现症状的风险，包括疲劳[OR：0.18，95％CI：（0.03，0.95）]，厌食症[OR：0.30，95%CI：（0.09，0.96）]，和不适应[OR：0.20，95%CI：（0.06，0.67）]。
结论：LAM人群的疫苗接种率低于一般人群，22.7%(41/181)的LAM患者对COVID-19疫苗有犹豫。然而,LAM队列中COVID-19疫苗接种的安全性与健康人群相当，和COVID-19疫苗接种降低了LAM患者COVID-19症状的发生率。此外,mTOR抑制剂似乎不能确定COVID-19期间LAM患者出现并发症的风险更大。
